Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants.

Lee, Sun Ku

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants. [electronic resource] - European journal of clinical pharmacology Jun 2017 - 689-698 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial

1432-1041

10.1007/s00228-017-2226-2 doi


Adolescent
Adult
Agammaglobulinaemia Tyrosine Kinase
Antigens, CD--metabolism
Antigens, Differentiation, T-Lymphocyte--metabolism
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Drug Interactions
Half-Life
Humans
Isoquinolines--administration & dosage
Lectins, C-Type--metabolism
Male
Methotrexate--administration & dosage
Middle Aged
Oligopeptides--administration & dosage
Protein Kinase Inhibitors--administration & dosage
Protein-Tyrosine Kinases--antagonists & inhibitors
Young Adult